Investors bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading hours on Thursday. $152.20 million flowed into the stock on the tick-up and $116.59 million flowed out of the stock on the tick-down, for a money net flow of $35.61 million into the stock. Of all companies tracked, Johnson & Johnson had the 10th highest net in-flow for the day. Johnson & Johnson traded down ($0.13) for the day and closed at $122.51

A number of research firms recently commented on JNJ. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Johnson & Johnson in a research report on Sunday, April 17th. Royal Bank Of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Sunday, April 17th. BTIG Research reissued a “hold” rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Finally, Piper Jaffray Cos. raised their target price on shares of Johnson & Johnson from $105.00 to $106.00 and gave the company a “neutral” rating in a report on Wednesday, April 20th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $112.36.

The stock’s 50-day moving average price is $116.31 and its 200-day moving average price is $108.77. The company has a market cap of $336.98 billion and a P/E ratio of 22.33.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 19th. The company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.65 by $0.03. The company earned $17.50 billion during the quarter, compared to the consensus estimate of $17.50 billion. During the same quarter last year, the company posted $1.56 earnings per share. The firm’s revenue for the quarter was up .6% on a year-over-year basis. Analysts expect that Johnson & Johnson will post $6.61 earnings per share for the current fiscal year.

In related news, VP Gary J. Pruden sold 9,735 shares of the company’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $116.03, for a total value of $1,129,552.05. Following the transaction, the vice president now directly owns 43,630 shares in the company, valued at $5,062,388.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Ronald A. Kapusta sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $115.79, for a total transaction of $347,370.00. Following the completion of the transaction, the chief accounting officer now owns 28,725 shares in the company, valued at $3,326,067.75. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have modified their holdings of the company. World Asset Management Inc boosted its position in shares of Johnson & Johnson by 3.5% in the fourth quarter. World Asset Management Inc now owns 307,991 shares of the company’s stock worth $31,637,000 after buying an additional 10,434 shares during the last quarter. San Francisco Sentry Investment Group CA boosted its position in shares of Johnson & Johnson by 4.8% in the fourth quarter. San Francisco Sentry Investment Group CA now owns 18,551 shares of the company’s stock worth $1,906,000 after buying an additional 842 shares during the last quarter. Clean Yield Group boosted its position in shares of Johnson & Johnson by 3.2% in the fourth quarter. Clean Yield Group now owns 58,316 shares of the company’s stock worth $5,760,000 after buying an additional 1,800 shares during the last quarter. MU Investments Co. Ltd. boosted its position in shares of Johnson & Johnson by 570.8% in the fourth quarter. MU Investments Co. Ltd. now owns 45,950 shares of the company’s stock worth $4,743,000 after buying an additional 39,100 shares during the last quarter. Finally, Spinnaker Trust boosted its position in shares of Johnson & Johnson by 0.5% in the fourth quarter. Spinnaker Trust now owns 79,412 shares of the company’s stock worth $8,157,000 after buying an additional 373 shares during the last quarter.

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.